l-epigallocatechin
Small moleculeexperimental
Epigallocatechin gallate (EGCG), also known as epigallocatechin-3-gallate, is the ester of epigallocatechin and gallic acid, and is a type of catechin. — Wikipedia
Clinical trial activity
129 trials · 152 clinical orgs · 0 marketing orgs
Phase 1
20
Phase 2
49
Phase 3
23
Phase 4
2
Earliest trial started Dec 1, 1997 (NCT00003197)
Timeline
Indications
Approved for
Studied for
- Affect · Phase 4
- Alzheimer Disease · Phase 2/Phase 3
- Amyloidosis · Phase 2
- Angina, Stable · Phase 2
- Arthritis, Rheumatoid · Phase 3
- Autoimmune Diseases · Phase 2
- Brain Injuries, Traumatic · Phase 2/Phase 3
- Breast Neoplasms · Phase 2
- Carcinoma, Squamous Cell · Phase 3
- Cardiovascular Diseases · Phase 2
- Cognition · Phase 4
- Colorectal Neoplasms · Phase 2
- COVID-19 · Phase 2/Phase 3
- Deglutition Disorders · Phase 2
- Dermatitis · Phase 2
- Diabetes Mellitus · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 3
- Diabetic Nephropathies · Phase 2
- Diabetic Retinopathy · Phase 1
- Down Syndrome · Phase 2
- Drug-Related Side Effects and Adverse Reactions · Phase 1/Phase 2
- Drugs, Investigational · Phase 3
- Endometriosis · Phase 2
- Esophageal Neoplasms · Phase 2
- Esophagitis · Phase 2
- Fetal Alcohol Spectrum Disorders · Phase 2/Phase 3
- Frailty · Phase 2
- Glaucoma, Open-Angle · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1
- Healthy Volunteers · Phase 1
- Heart Diseases · Phase 2
- Hepatitis C · Phase 3
- Hepatitis C, Chronic · Phase 1
- Huntington Disease · Phase 2
- Hypercholesterolemia · Phase 2
- Hyperlipidemias · Phase 3
- Hypertension · Phase 2
- Idiopathic Pulmonary Fibrosis · Phase 1/Phase 2
- Inflammation · Phase 2
- Inositol · Phase 3
- Insulin Resistance · Phase 2
- Leiomyoma · Phase 3
- Lichen Planus, Oral · Phase 3
- Liver Cirrhosis · Phase 2
- Lung Diseases, Interstitial · Phase 2
- Lung Neoplasms · Phase 2
- Lupus Erythematosus, Systemic · Phase 2
- Metabolism · Phase 4
- Mucositis · Phase 1/Phase 2
- Multiple Sclerosis · Phase 2/Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 1/Phase 2
- Multiple System Atrophy · Phase 3
- Muscular Dystrophy, Duchenne · Phase 2/Phase 3
- Nasopharyngeal Carcinoma · Phase 2/Phase 3
- Neoplasms · Phase 2
- Obesity · Phase 3
- Ocular Hypertension · Phase 1/Phase 2
- Osteoporosis · Phase 1/Phase 2
- Oxidative Stress · Phase 1
- Parkinson Disease · Phase 2
- Prostatic Neoplasms · Phase 2/Phase 3
- Radiodermatitis · Phase 3
- Small Cell Lung Carcinoma · Phase 1
- Triple Negative Breast Neoplasms · Early Phase 1
- Tuberculosis · Phase 1
- Uterine Cervical Neoplasms · Phase 2
- Vitamin B 6 · Phase 3
- Vitamin D · Phase 3
- Weight Loss · Phase 1
Mechanism of action
- Unspecified targetAntioxidant
antioxidant
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEpigallocatechin gallate ↗
Also known as
- 3,3',4',5,5',7-flavanhexol
- 3,3',4',5,5',7-flavanhexol
- antiscurvy factor c2
- antiscurvy factor c2
- egc
- egc
- egcg
- egcg
- egcg
- egcg cpd
- epgcg
- epigallocatechin
- epigallocatechin
- epigallocatechin
- epigallocatechin
- (-)-epigallocatechin
- (-)-epigallocatechin
- (-)-epi-gallocatechin
- (-)-epi-gallocatechin
- (−)-epigallocatechin
- (−)-epigallocatechin
- epi-gallocatechin
- epi-gallocatechin
- epigallocatechin-3-gallate
- epigallocatechin-3-gallate
- epigallocatechin-3-gallate
- epigallocatechin-3-o-gallate
- epigallocatechingallate
- epigallo-catechin gallate
- epigallocatechin gallate
- epigallocatechin gallate
- epigallocatechin gallate
- epigallocatechin gallate
- epigallocatechol
- (-)-epigallocatechol
- (-)-epigallocatechol
- gallocatechin
- gallocatechol
- gallocatechol, (2r-cis)-isomer
- gallocatechol, (2r-trans)-isomer
- gallocatechol, (2s-trans)-isomer
- galloepicatechin
- galloepicatechin
- green tea extract
- green tea extract
- green tree extract
- l-epigallocatechin
- l-epigallocatechin
- polyphenol
- polyphenol
- polyphenols
- polyphenols
- teavigo
- teavigo
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07149506 | Phase 3 | Sep 1, 2025 | Hospital Regional Alta Especialidad Bajio, Universidad de Guanajuato |
| NCT06992661 | Phase 1 | Jun 1, 2025 | Jiao Tong University |
| NCT06531863 | N/A | Sep 1, 2024 | Auburn University |
| NCT06661083 | N/A | Aug 1, 2024 | AGUNCO Obstetrics and Gynecology Centre |
| NCT06398405 | Phase 2 | Apr 22, 2024 | Shandong University |
| NCT06265532 | Phase 1 | Feb 7, 2024 | Cornell University, Harvard University, National Heart, Lung, and Blood Institute (NHLBI), University of California, San Francisco, University of Michigan |
| NCT06068543 | Phase 2 | Jan 1, 2024 | University of Rochester |
| NCT06015022 | Phase 2 | Dec 1, 2023 | The University of Texas, Dallas |
| NCT06524609 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2023 | Shandong University |
| NCT06098456 | Phase 2 | Nov 1, 2023 | Centro di Ricerca Clinica Salentino |
| NCT05988788 | N/A | Oct 31, 2023 | Cairo University |
| NCT05811403 | N/A | Jul 1, 2023 | Cairo University |
| NCT06924749 | Phase 2 | Jun 5, 2023 | Shandong University |
| NCT05195918 | Phase 1 | Mar 1, 2023 | Cornell University, Harvard University, Temple University, University of California, San Francisco, University of Michigan, University of Washington |
| NCT05758571 | Phase 1/Phase 2 (Phase 2) | Jan 5, 2023 | Shandong University |
| NCT05680662 | Early Phase 1 (Phase 1) | Jan 1, 2023 | Government of Saudi Arabia |
| NCT05409872 | N/A | Sep 15, 2022 | University of Verona |
| NCT05625308 | N/A | Jul 1, 2022 | Lo.Li. Pharma, Ltd. |
| NCT05448365 | Phase 3 | Jul 1, 2022 | Lo.Li. Pharma, Ltd. |
| NCT05116098 | Phase 1 | Nov 30, 2021 | Government of Saudi Arabia |
Showing 20 of 129 trials
Page 1 / 7
Organizations
Research & Development (152)
152 organizations
Page 1 / 8